Passage Bio (NASDAQ:PASG) Announces Quarterly Earnings Results, Hits Estimates

Passage Bio (NASDAQ:PASG) posted its quarterly earnings data on Tuesday. The company reported ($1.47) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.47), FiscalAI reports.

Passage Bio Stock Performance

Shares of PASG stock opened at $4.00 on Thursday. The firm’s 50 day moving average price is $4.13 and its two-hundred day moving average price is $5.96. Passage Bio has a 52-week low of $3.29 and a 52-week high of $20.00. The stock has a market cap of $12.88 million, a PE ratio of -0.39 and a beta of 1.51.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Wall Street Zen downgraded Passage Bio from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings upgraded Passage Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, November 2nd. Two research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Passage Bio has a consensus rating of “Hold” and an average target price of $13.25.

About Passage Bio

Passage Bio, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for diseases of the central nervous system. The company uses adeno-associated virus (AAV) delivery technologies to develop treatments intended to address the underlying genetic causes of severe neurological and neurodegenerative disorders. Its research programs have included PBGM01, an investigational gene therapy for GM1 gangliosidosis, a rare inherited disorder caused by mutations affecting the GLB1 gene.